---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-001119"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:58:57.455361+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioCryst reports record FY2025 operating profit; ORLADEYO rev $601.8M (+38%); maintains FY2026 guidance

## Summary
- Full year 2025 GAAP operating profit $341.0M vs loss of $2.5M in 2024; total revenues $874.8M (incl $243.3M European sale) vs $450.7M.
- Non-GAAP total revenues $592.9M (+45% YoY); non-GAAP operating profit $214.2M (+198%).
- ORLADEYO net revenue $601.8M (+38% YoY; +43% ex-EU); FY2026 revenue guidance maintained at $625-645M.
- Completed acquisition of Astria Therapeutics (navenibart); FDA approved ORLADEYO oral pellets for pediatric HAE.
- Cash $337.5M at year-end; net cash generation $85.2M ex-debt payoff and EU sale proceeds.

## SEC filing metadata
- accession: 0001171843-26-001119
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184326001119/0001171843-26-001119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184326001119/f8k_022626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-001119
- JSON: https://secwatch.observer/filing/0001171843-26-001119.json
- Plain text: https://secwatch.observer/filing/0001171843-26-001119.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.